Inventor · disambiguated record
Paul J. Maddon
Also filed as: MADDON PAUL J
48 granted patents·40 pending applications·1,106 citations·filing 1987–2022
99Inventor score
Top patents by PatentIndex Score
88 records- 0196US8470330B2PSMA antibodies and uses thereofMADDON PAUL J·Filed 2010·Granted Jun 25, 2013·50 cites·31 claims
- 0295US8114965B2Compositions of PSMA antibodiesMADDON PAUL J·Filed 2007·Granted Feb 14, 2012·52 cites·47 claims
- 0395US7592014B2Stabilized viral envelope proteins and uses thereofPROGENICS PHARM INC·Filed 2005·Granted Sep 22, 2009·34 cites·17 claims
- 0495US7345153B2Compounds capable of inhibiting HIV-1 infectionPROGENICS PHARM INC·Filed 2006·Granted Mar 18, 2008·23 cites·7 claims
- 0594US7060273B2Methods for inhibiting HIV-1 infectionPROGENICS PHARM INC·Filed 2002·Granted Jun 13, 2006·32 cites·24 claims
- 0694US6692745B2Compositions and methods for inhibition of HIV-1 infectionPROGENICS PHARM INC·Filed 2000·Granted Feb 17, 2004·37 cites·15 claims
- 0793US7122185B2Anti-CCR5 antibodyPDL BIOPHARMA INC·Filed 2003·Granted Oct 17, 2006·50 cites·75 claims
- 0893US6710173B1Stabilized viral envelope proteins and uses thereofPROGENICS PHARM INC·Filed 2000·Granted Mar 23, 2004·36 cites·30 claims
- 0992US9695248B2PSMA antibodies and uses thereofMADDON PAUL J·Filed 2012·Granted Jul 4, 2017·9 cites·31 claims
- 1092US7666419B2Anti-CCR5 antibodyPROGENICS PHARM INC·Filed 2006·Granted Feb 23, 2010·14 cites·36 claims
- 1192US6344545B1Method for preventing HIV-1 infection of CD4+ cellsPROGENICS PHARM INC·Filed 1997·Granted Feb 5, 2002·91 cites·6 claims
- 1291US7118859B2Methods for inhibiting HIV-1 infectionPROGENICS PHARM INC·Filed 2001·Granted Oct 10, 2006·30 cites·8 claims
- 1391US7022324B2Stabilized viral envelope proteins and uses thereofPROGENICS PHARM INC·Filed 2001·Granted Apr 4, 2006·31 cites·20 claims
- 1490US7138119B2Compositions and methods for inhibition of HIV-1 infectionPROGENICS PHARM INC·Filed 2001·Granted Nov 21, 2006·24 cites·15 claims
- 1589US7850971B2PSMA antibodies and protein multimersPSMA DEV COMPANY LLC·Filed 2003·Granted Dec 14, 2010·42 cites·27 claims
- 1689US6034223ANon-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 immunoconjugates, and uses thereofPROGENICS PHARM INC·Filed 1995·Granted Mar 7, 2000·69 cites·8 claims
- 1788US8821877B2Methods for inhibiting HIV-1 replication involving the administration of an anti-CCR5 receptor monoclonal antibody and small molecule CCR5 receptor antagonistOLSON WILLIAM C·Filed 2010·Granted Sep 2, 2014·10 cites·19 claims
- 1887US5817767ASynergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using samePROGENICS PHARM INC·Filed 1993·Granted Oct 6, 1998·73 cites·6 claims
- 1986US6261763B1Fluorescence resonance energy transfer screening assay for the identification of compounds that are capable of abrogating macrophage-tropic HIV-1 cell fusionPROGENICS PHARM INC·Filed 1996·Granted Jul 17, 2001·38 cites·9 claims
- 2086US6107019AMethod for preventing HIV-1 infection of CD4+ cellsPROGENICS PHARM INC·Filed 1997·Granted Aug 22, 2000·78 cites·12 claims
- 2183US7851600B2Anti-CCR5 antibodyPROGENICS PHARM INC·Filed 2006·Granted Dec 14, 2010·3 cites·27 claims
- 2283US5110906ADerivatives of soluble T-4UNIV COLUMBIA·Filed 1988·Granted May 5, 1992·27 cites·3 claims
- 2382US7736649B2Methods of inhibiting human immunodeficiency virus infection through the administration of synergistic combinations of anti-CCR5 monoclonal antibodies, fusion inhibitors, and CD4-GP120 binding inhibitorsPROGENICS PHARM INC·Filed 2006·Granted Jun 15, 2010·1 cites·23 claims
- 2479US7479553B2Nucleic acids encoding mutant disulfide bond-stabilized human immunodeficiency virus type 1 (HIV-1) gp140 envelope glycoproteinsPROGENICS PHARM INC·Filed 2004·Granted Jan 20, 2009·4 cites·52 claims
- 2578US7022323B2Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infectionPROGENICS PHARM INC·Filed 2002·Granted Apr 4, 2006·3 cites·23 claims
- 2677US7935797B2CCR5 chemokine receptor-specific monoclonal antibodies capable of inhibiting HIV-1 cell fusionPROGENICS PHARM INC·Filed 2007·Granted May 3, 2011·1 cites·1 claims
- 2777US6972126B2Methods for using resonance energy transfer-based assay of HIV-1 envelope glycoprotein-mediated membrane fusion, and kits for practicing samePROGENICS PHARM INC·Filed 1999·Granted Dec 6, 2005·33 cites·3 claims
- 2877US5126433ASoluble forms of the t cell surface protein cd4UNIV COLUMBIA·Filed 1987·Granted Jun 30, 1992·50 cites·2 claims
- 2976US6737267B2Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 immunoconjugates, and uses thereofPROGENICS PHARM INC·Filed 2001·Granted May 18, 2004·3 cites·48 claims
- 3074US6093539ADNA encoding the T cell surface protein T4 and use of fragments of T4 in the treatment of AIDSUNIV COLUMBIA·Filed 1995·Granted Jul 25, 2000·36 cites·28 claims
- 3171US2023192891A1ACE2-Targeted Compositions and Methods for Treating COVID-19MADDON ADVISORS LLC·Filed 2021·Application pending·0 cites
- 3270US2022056153A1ACE2-Targeted Compositions and Methods for Treating COVID-19MADDON ADVISORS LLC·Filed 2021·Application pending·0 cites
- 3370US2007274986A1Compositions comprising anti-CCR5 antibodyPROGENICS PHARM INC·Filed 2007·Application pending·0 cites
- 3470US2022098283A1ACE2- and TMPRSS2-Targeted Compositions and Methods for Treating COVID-19MADDON ADVISORS LLC·Filed 2021·Application pending·0 cites
- 3570US2009155774A1Fluorescence resonance energy transfer screening assay for the identification of HIV-1 envelope glycoprotein-medicated cellPROGENICS PHARM INC·Filed 2009·Application pending·0 cites
- 3668US6451313B1CD4-gamma2 and CD4-IGG2 chimerasPROGENICS PHARM INC·Filed 1995·Granted Sep 17, 2002·29 cites·9 claims
- 3768US2014377259A1Methods for inhibiting hiv-1 replication involving the administration of an anti-ccr5 receptor monoclonal antibody and small molecule ccr5 receptor antagonistCYTODYN INC·Filed 2014·Application pending·0 cites
- 3867US5886163AHIV-1 antigens, antibody compositions related thereto, and therapeutic and prophylactic uses thereofPROGENICS PHARM INC·Filed 1994·Granted Mar 23, 1999·17 cites·9 claims
- 3967US2008241135A1Methods for reducing viral load in HIV-1-infected patientsPROGENICS PHARM INC·Filed 2007·Application pending·0 cites
- 4066US6177549B1Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 immunoconjugates, and uses thereofPROGENICS PHARM INC·Filed 1999·Granted Jan 23, 2001·10 cites·8 claims
- 4164US2005215472A1PSMA formulations and uses thereofPSMA DEV COMPANY LLC·Filed 2004·Application pending·0 cites
- 4264US2024409659A1ACE2-Targeted Compositions and Methods for Treating COVID-19Maddon Advisore LLC·Filed 2022·Application pending·0 cites
- 4364US2004228869A1Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies theretoPROGENICS PHARM INC·Filed 2004·Application pending·0 cites
- 4463US7901685B2Methods for assaying inhibition of HIV-1 envelope glycoprotein-mediated membrane fusionPROGENICS PHARM INC·Filed 2005·Granted Mar 8, 2011·0 cites·3 claims
- 4563US2020306372A1Methods for reducing viral load in hiv-1 infected patientsCYTODYN INC·Filed 2019·Application pending·0 cites
- 4663US2008226651A1Compounds capable of inhibiting hiv-1 infectionPROGENICS PHARM INC·Filed 2008·Application pending·0 cites
- 4762US2007231327A1Anti-CCR5 antibodiesPROGENICS PHARM INC·Filed 2007·Application pending·0 cites
- 4862US2007026441A1Methods for reducing viral load in HIV-1-infected patientsOLSON WILLIAM C·Filed 2006·Application pending·0 cites
- 4960US7862994B2Methods for inhibiting HIV-1 envelope glycoprotein-medicated membrane fusionPROGENICS PHARM INC·Filed 2001·Granted Jan 4, 2011·0 cites·4 claims
- 5060US2004062767A1Compositions and methods for inhibition of HIV-1 infectionPROGENICS PHARM INC·Filed 2003·Application pending·0 cites
Showing the top 50 of 88 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Paul J. Maddon files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →